![]() All other trademarks are property of their respective owners. All references for B-Laser on this website, supporting documents including publications and on the device labeling for this study, refer to the Auryon Atherectomy System.ĪngioDynamics, Auryon, and B-Laser are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. Both names (B-Laser and the Auryon Atherectomy System, also referred to simply as “Auryon”) refer to the same device. The Auryon Atherectomy System’s solid-state laser technology will be made available to providers and. AngioDynamics has acquired Eximo Medical and its proprietary 355-nm wavelength laser technology platform. The 1470 nm laser allows effective vein ablation with the targeted energy of 30-50 joules/cm at a setting of 5-7 watts. Maximizing these two technologies can result in even better patient outcomes 1. ![]() In 2020, the name “B-Laser” was replaced by the Auryon Atherectomy System. Management believes the Auryon Atherectomy System is path-breaking for the treatment of PAD. It is designed to work exclusively with the range of AngioDynamics fibers, including the NeverTouch fibers. GENERAL NOTE: B-Laser was the initial name of the device. At present, real-world data are not available. The device is based on solid-state laser technology. Background: The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the investigational device exemption study. Acute and 30-day safety and effectiveness evaluation of Eximo Medical’s B-Laser, a novel atherectomy device, in subjects affected with infrainguinal peripheral arterial disease: Results of the EX-PAD-03 trial. In September 2020, AngioDynamics announced the commercial launch of their Auryon Atherectomy System in the United States. Shammas NW, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al.Acute and 30-day safety and effectiveness evaluation of Eximo Medical’s B-Laser, a novel atherectomy device, in subjects affected with infrainguinal peripheral arterial disease: Results of the EX-PAD-03 trial. Investigation Device Exemption (IDE) Trial evaluating the B-Laser™ in patients with symptomatic PAD Dissections Following Auryon Laser Atherectomy and Adjunctive Balloon Angioplasty: results of the iDissection Auryon Laser Study. Shammas NW, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. 6-month pivotal data from the EX-PAD-03 U.S. Atherectomy using a solid-state laser at 355 nm wavelength. In acquiring Eximo and its laser technology, AngioDynamics enters a growing 500+ million market with an innovative medical solution. Herzog A, Oszkinis G, Planer D, et al. Physicians provide atherectomy treatment to over 200,000. The Auryon laser atherectomy system (AngioDynamics, Inc.However, the extent of facilitated angioplasty is dependent on the device and baseline lesion morphology, consistent with the need for lesion-specific coronary intervention. Rotational atherectomy, extraction atherectomy and excimer laser angioplasty can facilitate the results of balloon angioplasty. Facilitated angioplasty was also observed after extraction atherectomy and excimer laser angioplasty for ostial lesions, but not for any other lesion subsets. Quantitative angiographic analysis included final lumen diameter, final diameter stenosis and efficiency of balloon-mediated lumen enlargement.Ĭompared with angioplasty alone (33 +/- 12% ), final diameter stenosis was higher for adjunctive angioplasty after extraction atherectomy (37 +/- 16%, p 20 mm long. ![]() ![]() This study sought to determine whether adjunctive balloon angioplasty after rotational atherectomy and excimer laser angioplasty provides better lumen enlargement ("facilitated angioplasty") than angioplasty alone.Īdjunctive angioplasty is often used immediately after atherectomy and laser angioplasty to further enlarge lumen dimensions, but it is not known whether this practice is superior to angioplasty alone.īalloon angioplasty was performed in 1,266 native coronary lesions alone (n = 541) or after extraction atherectomy (n = 277), rotational atherectomy (Rotablator) (n = 211) or excimer laser angioplasty (n = 237).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |